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Abstract
Background: Dupuytren's Disease (DD) is a debilitating contractile fibrosis of the palmar fascia
characterised by excess collagen deposition, contractile myofibroblast development, increased
Transforming Growth Factor-β levels and β-catenin accumulation. The aim of this study was to
determine if a collagen-enriched environment, similar to in vivo conditions, altered β-catenin
accumulation by primary DD cells in the presence or absence of Transforming Growth Factor-β.
Methods: Primary DD and patient matched, phenotypically normal palmar fascia (PF) cells were
cultured in the presence or absence of type-1 collagen and Transforming Growth Factor-β1. β-
catenin and α-smooth muscle actin levels were assessed by western immunoblotting and
immunofluorescence microscopy.
Results: DD cells display a rapid depletion of cellular β-catenin not evident in patient-matched PF
cells. This effect was not evident in either cell type when cultured in the absence of type-1 collagen.
Exogenous addition of Transforming Growth Factor-β1 to DD cells in collagen culture negates the
loss of β-catenin accumulation. Transforming Growth Factor-β1-induced α-smooth muscle actin,
a marker of myofibroblast differentiation, is attenuated by the inclusion of type-1 collagen in
cultures of DD and PF cells.
Conclusion: Our findings implicate type-1 collagen as a previously unrecognized regulator of β-
catenin accumulation and a modifier of TGF-β1 signaling specifically in primary DD cells. These data
have implications for current treatment modalities as well as the design of in vitro models for
research into the molecular mechanisms of DD.
Background
Dupuytren's contracture, or Dupuytren's Disease, (DD)
[1-3] is a common, benign palmar fibromatosis of
unknown etiology that results in finger contracture and
loss of hand function. The most widely accepted treat-
ment is surgical resection of the disease cord, an approach
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associated with prolonged post-operative rehabilitation
and high recurrence rates [4,5]. Recently, minimally inva-
sive treatment alternatives such as clostridial collagenase
injection [6,7] and needle aponeurotomy [8-10] have
gained popularity. While these approaches require rela-
tively little post-treatment rehabilitation, their long-term
efficacy and disease recurrence rates relative to fasciec-
tomy are yet to be clearly established.
We and others have identified dysregulated genes in pri-
mary cultures of DD cells [11] or DD cord and nodule tis-
sue [12-14]. Many of these gene transcripts encode
extracellular matrix (ECM)-associated proteins, including
several types of collagen. Biochemical analyses of DD cord
demonstrate the abundance of type I and III collagen [15-
17] with type IV and other collagens present to a lesser
extent [18].
As with many fibroproliferative conditions, DD is associ-
ated with alterations in Transforming Growth Factor
(TGF)-β signaling pathways [19-25] and this cytokine pro-
motes both collagen production and contractile myofi-
broblast development in this disease [26,27]. TGF-β1 has
been shown to stimulate fibroblast proliferation by induc-
ing β-catenin accumulation and transactivation of the Tcf/
Lef transcription complex during normal and abnormal
cutaneous wound repair [28-30]. Primary DD fibroblasts
are reported to have an enhanced sensitivity to TGF-β1
signaling [31] and we have previously documented that
surgically resected DD cord contains elevated levels of β-
catenin [32], implying that TGF-β induced β-catenin accu-
mulation may promote fibroblast proliferation in DD. We
have also previously demonstrated that β-catenin levels
are altered by isometric tension and ECM-cellular interac-
tions in three dimensional collagen culture in DD cells
relative to palmar fascia (PF) cells derived from the same
patients [32-34]. These findings suggest that isometric
tension during FPCL contraction, collagen interactions or
both differentially regulate β-catenin accumulation in
these cultures and that changes in β-catenin levels may
also be a component of increased contractility that DD
cells display relative to patient matched PF cells.
To discern the contribution of collagen to the regulation
of cellular β-catenin levels, we have cultured DD and PF
cells on type-1 collagen-coated trays in the absence of
three-dimensional contraction with or without exogenous
addition of TGF-β1. We hypothesized that the presence of
type-1 collagen in DD cell cultures, designed to more
closely recapitulate in vivo conditions, would differentially
regulate the responsiveness of DD and/or PF cells to envi-
ronmental stimuli such as TGF-β1 resulting in changes in
β-catenin accumulation.
Methods
Clinical Specimen collection
Surgically resected Dupuytren's Disease (DD) cord and
small samples of phenotypically normal palmar fascia tis-
sue (PF) were collected from patients undergoing primary
surgical resection of DD at the Hand and Upper Limb
Centre, London, Ontario. None of these patients were
being treated for recurrent disease. All subjects provided
written informed consent under institutional review
board approval and specimens were collected with the
approval of the University of Western Ontario Research
Ethics Board for Health Sciences Research involving
Human Subjects (HSREB protocol # 08222E).
Primary cell culture
Primary cells were isolated from surgically resected DD
cord and adjacent, phenotypically normal palmar fascia
using routine tissue culture practice as previously
described [34]. In brief, tissues were aseptically dissected
and pressed onto 100 mm culture dishes in α-MEM-
medium supplemented with 10% fetal bovine serum
(FBS, Invitrogen Corporation, Carlsbad, CA) and 1% anti-
biotic-antimycotic solution (Sigma-Aldrich, St Louis,
MO). Once cellular outgrowths from the tissue fragments
were evident, the cells are passaged by routine trypiniza-
tion. Primary cells isolated by this procedure invariably
display a fibroblastic morphology. Six DD cord-derived
cell cultures and six patient-matched PF-derived cell cul-
tures were used for these experiments.
For  in vitro culture on collagen, collagen fibers were
mechanically extracted from rat tail tendons (adapted
from [35]), placed under UV light overnight and then
incubated in sterile acetic acid, with mechanical stirring
for 7 days at 4°C. Undissolved collagen fibers were
removed by centrifugation at 10,000 × g at 4°C for two
hours. Collagen concentration was determined using the
Sircol Collagen Quantification assay (Biocolor Ltd., Car-
rickfergus, UK). For tissue culture, collagen monolayers
were cast in 6-well tissue culture trays with each well con-
taining 800 μl collagen and 200 μl of the neutralization
solution (2 parts 0.34 N NaOH and 3 parts 10× Way-
mouth media) to a final concentration of 1.9 mg/ml. Fol-
lowing collagen polymerization, primary cells were added
in α-MEM, 10% FBS and 1% antibiotic-antimycotic solu-
tion at 37°C in 5% CO2 for 72 hours. After 72 hours,
media was aspirated from each well and cells were treated
as described in the text.
Recombinant Transforming Growth Factor (TGF)β-1
(R&D Systems, Minneapolis, MN) was included in cell
cultures as described in the text.BMC Musculoskeletal Disorders 2009, 10:72 http://www.biomedcentral.com/1471-2474/10/72
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Immunoblotting
Cells cultured on collagen coated trays were washed with
PBS prior to treatment with Collagenase XI (Sigma-
Aldrich, St. Louis, MO) to dislodge the adherent cells. The
cells were pelleted by centrifugation and cell lysates were
prepared in PhosphoSafe protein Extraction Buffer in
accordance with the manufacturer's instruction. Cell
grown on tissue culture plastic trays were lysed directly in
PhosphoSafe protein Extraction Buffer. After centrifuging
the extracts to remove insoluble material, equivalent pro-
tein quantities were determined by BCA analysis, sub-
jected to immunoblotting and probed with antibodies
against  β-catenin (BD Biosciences, Mississauga ON), α
smooth muscle actin (AbCam, Cambridge MA) and β
Actin (Labvision, Fremont, CA). Immunoblot analysis
was carried out using standard procedures and immuno-
reactivity was visualized using Enhanced Chemilumines-
cence (ECL). A minimum of three and a maximum of six
DD and patient-matched PF cell cultures were used for
these experiments. All immunoblots were repeated a min-
imum of three times and representative blots are shown.
Intensity of signals relative to β-actin controls were calcu-
lated by densitometry using ImageJ software http://
rsbweb.nih.gov/ij/index.html and averages of arbitrary
densitometry units and standard error of data obtained
from at least 3 independent experiments were calculated.
Paired t-tests were used to assess the significance of differ-
ences between groups. Results were deemed significant
when p < 0.05.
Immunofluorescence microscopy
Cells cultured on collagen were fixed with 4% paraformal-
dehyde in PBS for 20 min and permeabilized with 0.1%
Triton X-100 in PBS for 15 min. The preparations were
then blocked with 5% non-fat skim milk for 1 hr in PBS.
Cells were stained for DNA (DAPI) actin stress fibers
(Alexa 488 phallodin, Molecular Probes, Eugene OR), and
β-catenin (TRITC-conjugated anti-β-catenin, BD Bio-
sciences, Mississauga ON). All images were captured using
a CoolSnap digital camera attached to an IX81 Olympus
Inverted Microscope. Three DD and three patient-
matched PF cell cultures were used for these experiments.
All immunofluorescence studies were repeated three
times and representative images are shown.
Results
Collagen culture differentially regulates β-catenin 
accumulation in primary DD and PF cells
To distinguish the effects of collagen culture on β-catenin
levels from those induced by isometric tension in three
dimensional culture, primary DD and PF cells were cul-
tured on collagen coated dishes (1.9 mg/ml) in α-MEM-
medium supplemented with 10% FBS for 0, 24, 48 and 72
hours, lysed and β-catenin protein levels were assessed by
western blotting. As shown in Figure. 1A and 1B, DD cells
display a significant decrease in β-catenin levels at 72 hrs
not evident in PF cells derived from the same patient. To
confirm that this effect was not specific to these particular
cultures and the contribution of collagen to this pheno-
type, five additional patient-matched sets of DD and PF
cells were cultured for 72 hours on either tissue culture
plastic or collagen. The decrease in β-catenin levels at 72
hrs was evident in the DD cells from all additional
patients tested (two representative sets of patient-derived
samples are shown in Figure. 2A, densitometric analysis in
Figure. 2B) and collagen culture was required for this
effect to be evident. To further confirm this phenotype,
three matched sets of DD and PF cells were cultured on
collagen coated slides for 72 hours, fixed and stained with
Oregon green phalloidin and DAPI to label filamentous
actin and nuclei, respectively. β-catenin was detected
using primary β-catenin and TRITC-conjugated secondary
antibodies. As shown in the representative immunofluo-
rescence image in Figure. 3, PF cells exhibit readily detect-
able cytoplasmic β-catenin after 72 hours of culture on
collagen (Figure. 3A) while cytoplasmic β-catenin was at
low to undetectable levels in DD cells under identical cul-
ture conditions (Figure. 3B).
Collagen culture modifies TGFβ-1-induced β-catenin 
accumulation and α-smooth muscle actin expression in 
DD and PF cells
To determine if exogenous TGFβ-1 could rescue this loss
of cytoplasmic β-catenin accumulation, cells were cul-
tured in α-MEM-medium supplemented with 10% FBS
for 72 hours in the presence or absence of collagen, then
changed to α-MEM-medium supplemented with 2% FBS
and treated for 72 hours with 12.5 ng/ml TGFβ-1 or vehi-
cle. Our preliminary data (not shown) confirmed the
findings of Wong and Mudera [36] that 12.5 ng/ml of
TGFβ-1 optimally induced contraction and α-SMA pro-
duction by DD cells. As shown in Figure. 4A, exogenous
addition of TGFβ-1 enhanced cytoplasmic β-catenin accu-
mulation in DD cells cultured on collagen while levels
were comparatively unchanged by TGFβ-1 treatment of PF
cells under identical conditions. In the absence of colla-
gen, TGFβ-1 treatment did not alter significantly β-catenin
levels in either DD or PF cells. In contrast, TGFβ-1 treat-
ment resulted in strongly enhanced levels of α-SMA in the
absence of collagen and the addition of collagen markedly
attenuated this effect in both DD and PF cells (Figure 4B).
These changes, evident by visual inspection, were con-
firmed by densitometric analysis (Figure. 4D, E).
Discussion
The data reported here emphasize the importance of rec-
ognizing the disease environment as a major contributor
to changes in gene expression and cellular phenotype. We
have utilized in vitro models that mimic one aspect of the
in vivo DD environment, excess collagen deposition, andBMC Musculoskeletal Disorders 2009, 10:72 http://www.biomedcentral.com/1471-2474/10/72
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Type 1 collagen culture effects on β-catenin accumulation in DD and PF-cells Figure 1
Type 1 collagen culture effects on β-catenin accumulation in DD and PF-cells. A Representative western immunob-
lots of PF cells (PF1) and DD cells (PD1) cultured on type 1 collagen (1.9 mg/ml) for 0, 24, 48 and 72 hours prior to cell lysis 
and 8% PAGE, probed for β-catenin. Lysate from CaCo cells, which express high levels of β-catenin, was included as a positive 
control. β-actin levels were assessed by immunoblotting to confirm equal total protein loading. As indicated, (arrow) a 
decrease in β-catenin levels is evident in DD cells cultured on type 1 collagen for 72 hours. B Pooled densitometric analysis of 
triplicate analyses of the samples assessed in A normalized to β-actin. A significant decrease in band density indicating 
decreased β-catenin levels is evident in DD cells cultured on type 1 collagen for 72 hours relative to 0 hour cultures (*, p < 
0.05).
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Type 1 collagen culture effects on β-catenin accumulation are consistent between patient samples Figure 2
Type 1 collagen culture effects on β-catenin accumulation are consistent between patient samples. A Repre-
sentative western immunoblot analysis of additional patient matched sets of PF cells (PF2 and PF3) and DD cells (PD2 and PD3) 
cultured for 72 hours on either tissue culture plastic (Plc) or type 1 collagen (Col) and probed for β-catenin. β-actin levels 
were assessed to confirm equal total protein loading. As indicated, (arrows) a decrease in β-catenin levels is evident in DD cells 
cultured on collagen for 72 hours. B Pooled densitometric analysis of 6 patient matched PF and DD cell samples cultured for 
72 hours on type 1 collagen normalized to β-actin. As shown, a consistent, significant decrease in band density indicating 
decreased β-catenin levels is evident in DD cells cultured on type 1 collagen coated dishes for 72 hours relative to 0 hour cul-
tures (*, p < 0.05).
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show that this single addition results in rapid depletion of
cytoplasmic b-catenin levels and markedly alters DD cell
responses to TGFβ-1.
These studies utilized primary fibroblastic cells derived
from surgically resected DD cord tissue and patient-
matched, phenotypically normal palmar fascia. While sev-
eral studies have indicated that nodular tissue is inher-
ently more "biologically active" than cord tissue in vivo
[14,31,37,38], many have also noted that primary cells
derived from either of these structures are very similar in
appearance and responsiveness to TGFβ [31,37]. These
observations correlate with more recent studies indicating
that cells derived from primary nodule and cord have very
similar gene expression profiles [39]. As Dupuytren's Dis-
ease cords are surgically resected much more frequently
than nodules, we have utilized these abundant and bio-
logically useful tissues to allow us to compare multiple
matched pairs of primary cells in this study.
The collagen used for these experiments, extracted from
rat tail tendon, is primarily type 1 [40,41] while DD cord
has been reported to contain a mixture of type I and III
collagens [15-17] with type IV and other collagens present
to a lesser extent [18]. DD cord collagen is also reported
to feature increased levels of hydroxylysine and reducible
cross-links, biochemical changes associated with connec-
tive-tissue repair [42]. As collagen type III is an α1(III)3
homotrimer, while type I collagen is usually either an α
1(I)2 and α 2(I) heterotrimer or an α 1(I)3 homotrimer
[43], it is likely that our culture system, while closer to in
vivo conditions than plastic culture trays, does not recapit-
ulate some aspects of the DD cord environment. Future
studies will include determining if addition of type-III and
other collagens into our in vitro model system further
modifies any of the disease-specific responses identified
in this report.
Previous reports have indicated that primary DD cells are
more sensitive to a subset of cytokines including TGFβ-1
than phenotypically normal control cells [31,44]. We
have shown that a collagen-rich environment alters the
responses of DD cells to exogenous TGFβ-1, a well recog-
nized cytokine component of DD cord in vivo [26,27,45].
Contractile fibroblasts can activate latent TGFβ in the
ECM [46], suggesting the possibility that simultaneous
activation of mechano-receptors and latent, ECM-associ-
ated TGFβ may induce contractility in a positive feed-back
loop in this fibrosis. It is possible that the altered induc-
tion of α-SMA and β-catenin by TGFβ-1 treatment
reported here may reflect changes in substrate stiffness
between tissue-culture plastic and collagen surfaces,
thereby altering concurrent mechano-receptor and TGFβ
receptor activation.
TGFβ-1 signaling has been reported to utilize the combi-
natorial effects of other signaling molecules to direct
fibroblasts toward either a proliferative or a contractile
phenotype [47]. In our experimental system, type-1 colla-
gen was shown to modify cellular responses to exogenous
TGFβ-1, specifically increasing β-catenin accumulation in
DD cells and attenuating the increase in α-SMA levels in
both DD and PF cells. Overall, these data are consistent
Type 1 collagen culture effects on β-catenin accumulation in  DD and PF-cells Figure 3
Type 1 collagen culture effects on β-catenin accumu-
lation in DD and PF-cells. PF cells (A) and DD cells (B) 
were cultured on Type 1 collagen coated slides (1.9 mg/ml) 
for 72 hours. Cells were fixed and stained with Oregon 
green phalloidin (green) and DAPI (blue) to label filamentous 
actin and the nucleus, respectively. β-catenin was detected 
using primary beta-catenin and TRITC-conjugated secondary 
antibodies (orange). As shown, PF cells consistently displayed 
readily detectable peri-nuclear staining as well as diffuse 
staining throughout the cytoplasm after three days on colla-
gen culture. In contrast, DD cells displayed distinct β-catenin 
staining at the periphery of some cells adjacent to the cell 
membrane, with little or no β-catenin evident in the cyto-
plasm after three days on collagen culture.BMC Musculoskeletal Disorders 2009, 10:72 http://www.biomedcentral.com/1471-2474/10/72
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Type 1 collagen culture effects on TGF-β1 induced α-smooth muscle actin levels and β-catenin accumulation in DD and PF- cells Figure 4
Type 1 collagen culture effects on TGF-β1 induced α-smooth muscle actin levels and β-catenin accumulation in 
DD and PF-cells. Representative western immunoblot analysis of PF and DD cells cultured on tissue culture plastic ("Plastic") 
or type 1 collagen ("Collagen"), treated with TGFβ-1 or vehicle and assessed for α smooth muscle actin (A) and β-catenin (B) 
protein levels. β-actin levels (C) were assessed to confirm equal loading. Pooled densitometric analysis of α smooth muscle 
actin (D) and β-catenin (E) band density normalized to β-actin band density from triplicate experiments are shown. A signifi-
cant increase in β-catenin band density after TGFβ-1 treatment of DD cells cultured on collagen (*, p < 0.05) is evident relative 
to treated cells on plastic while the significant increase in α smooth muscle actin band density after TGFβ-1 treatment of DD 
cells growing on plastic (*, p < 0.05) is attenuated by collagen culture.
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with type-1 collagen modifying TGFβ-1 induced prolifer-
ation and contractile myofibroblast differentiation in DD.
It is currently unclear to what extent collagen acts to
sequester TGFβ-1, thereby decreasing its bioavailability,
or modifies cellular signaling cascades resulting in altered
cellular responses. Integrins are the primary mediators of
signals from the extra-cellular matrix that affect cellular
gene expression or changes in morphology [48,49]. We
speculate that novel combinations of integrins in DD cells
may mediate the increased sensitivity of DD cells to their
collagen-enriched environment. TGFβ1 can induce α5β1
expression in other cell types [50,51] and DD cord myofi-
broblasts are reported to express higher levels of α5β1
integrins than cells in surrounding tissues [52,53]. Type 1
collagen/β1 integrin interactions have been reported to
alter cytoplasmic β-catenin accumulation in tumor cells
through tyrosine kinase-mediated disruption of adherens
junctions [54]. We have previously reported tyrosine
phosphorylated β-catenin accumulation in collagen-rich
DD cord tissue [32], indicating that tyrosine kinase-medi-
ated adherens junction disruption may contribute to the
cytoplasmic β-catenin evident in DD tissue. Cytoplasmic
β-catenin levels are regulated through serine-9 phosphor-
ylation and inactivation of Glycogen Synthase kinase
(GSK)3β in the canonical pathway rather than through
changes in transcriptional activity of CTNNB1, the gene
encoding β-catenin [19]. Studies are currently underway
to assess both tyrosine phosphorylated β-catenin levels
and Glycogen Synthase kinase (GSK)3β activity in DD
and PF cells grown on collagen in the presence or absence
of TGFβ1 to clarify the source(s) of β-catenin in DD.
Current treatment for DD includes surgical resection of
the disease cord, clostridial collagenase injection and nee-
dle aponeurotomy. These procedures differ in the amount
of type-1 collagen-rich extra-cellular matrix remains in situ
after treatment. While it is premature to translate the in
vitro data reported here to treatment recommendations, it
is possible that treatment that disrupt mechanical tension
and deplete disease-associated collagen may have benefi-
cial effects on disease progression and recurrence beyond
mechanical disruption of the disease cord alone. In con-
trast, treatment that disrupt the DD cord and relieve
mechanical tension but do not alter the level of disease-
associated collagen within the fascia may allow DD-asso-
ciated fibroblasts to maintain their disease phenotype,
potentially resulting in higher rates of disease progression
and recurrence.
Conclusion
In summary, these findings implicate type-1 collagen as a
regulator of DD cell phenotype and emphasize the impor-
tance of modeling fibroproliferative diseases in general,
and DD in particular, in culture systems that include ECM
components of the in vivo disease environment.
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